Prostate cancer

@article{Rebello2021ProstateC,
  title={Prostate cancer},
  author={Richard J. Rebello and Christoph Oing and Karen E. Knudsen and Stacy Loeb and David C. Johnson and Robert E. Reiter and Silke Gillessen and Theodorus H. van der Kwast and Robert G. Bristow},
  journal={Nature Reviews Disease Primers},
  year={2021},
  volume={7},
  pages={1-27}
}
Prostate cancer is a complex disease that affects millions of men globally, predominantly in high human development index regions. Patients with localized disease at a low to intermediate risk of recurrence generally have a favourable outcome of 99% overall survival for 10 years if the disease is detected and treated at an early stage. Key genetic alterations include fusions of TMPRSS2 with ETS family genes, amplification of the MYC oncogene, deletion and/or mutation of PTEN and TP53 and, in… 

PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer

TLDR
The rationale for PARP inhibition in patients with prostate cancer is reviewed, the impact of PARP inhibitors on outcomes is discussed, and underlying challenges for future developments are explored.

Neoadjuvant Hormonal Therapy for Prostate Cancer: Morphologic Features and Predictive Parameters of Therapy Response.

TLDR
The morphologic changes associated with neoadjuvant-treated PCa are summarized, focusing on the predictive value of pathologic parameters to therapy response, and the evaluation system in the stratification of pathological response to NHT in PCa management is described.

Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer

TLDR
Four novel genes, including NPTX1, PCSK1, ASXL3, and TRIM9, were all significantly upregulated in NEPC compared with the adenocarcinoma samples, and these genes were all associated with the neuroactive ligand receptor interaction pathway.

Identification of a Gene Signature to Aid Treatment Decisions by Integrated Analysis of Mutated Genes Between Primary and Metastatic Prostate Cancer

TLDR
An integrated analysis of mutated genes between primary and metastatic prostate cancer and the prognostic value of riskscore is performed, which provides a novel assessment scheme to precisely select treatment strategies.

Outcome of 177Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer

TLDR
The study provides support for the expected shorter survival compared to heterogenous patient groups and indicates that radioligand therapy with 177Lu-PSMA-617 in metastasized castration-resistant early-onset prostate cancer patients refractory to chemotherapy yields similar response rates with a comparable safety profile, but is associated with shorter survival.

The Potential Tumor-Suppressor DHRS7 Inversely Correlates with EGFR Expression in Prostate Cancer Cells and Tumor Samples

TLDR
A tumor-suppressor role for DHRS7 by modulating EGFR expression in prostate cancer is suggested, and analysis of patient samples and proteome analyses suggest a protective role for the dehydrogenase/reductase 7 in PCa.

Advances and development of prostate cancer, treatment, and strategies: A systemic review

TLDR
The present review aims at discussing the development, diagnostics via machine learning, and implementation of treatment of prostate cancer with a special focus on nanotherapeutics, in the gulf countries.

Current and emerging therapies for neuroendocrine prostate cancer.

TLDR
Treatments currently in use to treat neuroendocrine prostate cancer, including platinum-based therapies, taxanes and etoposide are discussed, and ongoing clinical trials information is utilized to identify potential emerging therapies for neuroendocrin prostate cancer.

Prostate Cancer Brain Metastasis: Review of a Rare Complication with Limited Treatment Options and Poor Prognosis

TLDR
Overall, prostate cancer BM are rare and associated with poor prognosis, and future research is needed to study the impact of novel prostate cancer therapeutics on BM incidence, to identify patients at risk of BM, and to characterize molecular treatment targets.
...

References

SHOWING 1-10 OF 352 REFERENCES

Prostate cancer

Targeting Continued Androgen Receptor Signaling in Prostate Cancer

TLDR
Abiraterone acetate, an androgen biosynthesis inhibitor, was tested in patients with CRPC pretreated with docetaxel in a phase III trial with demonstration of an overall survival benefit, confirming that CRPC remains hormone driven, even in advanced stages of the disease.

Molecular genetics of prostate cancer.

TLDR
This review addresses recent progress toward the central objectives of understanding parameters of normal versus abnormal prostatic development and of elucidating a molecular pathway for prostate cancer progression and focuses on key regulatory molecules that have been implicated by analysis of patterns of allelic loss in human prostate cancers and/or by reverse genetic approaches in the mouse.

Management of low risk prostate cancer—active surveillance and focal therapy

TLDR
The rationale and current status of active surveillance is discussed, and whether and when focal therapy should complement it in those men wishing to continue a tissue-preserving strategy is commented on.

Genomics of lethal prostate cancer at diagnosis and castration resistance

TLDR
The genomics of diagnostic prostatic biopsies acquired from men who develop mCRPC differ from those of the nonlethal primary prostatic cancers, with RB1/TP53/AR aberrations are enriched in later stages, but the prevalence of DDR defects in diagnostic samples is similar to m CRPC.

Management of low risk prostate cancer: active surveillance and focal therapy

TLDR
Active surveillance is appropriate for most men with low-risk prostate cancer, and focal therapy may complement active surveillance for those men wishing to continue a tissue-preserving strategy.

The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer

TLDR
The mutational landscape of a heavily treated metastatic cancer is described, novel mechanisms of AR signalling deregulated in prostate cancer are identified, and candidates for future study are prioritize.

Aggressive Variants of Castration-Resistant Prostate Cancer

TLDR
Patients meeting clinical criteria of anaplastic prostate cancer have been shown to predict for poor prognosis, and these patients may be considered for platinum-based chemotherapy treatment regimens, so understanding variants within the spectrum of advanced prostate cancer has important diagnostic and treatment implications.
...